Date de publication: 30 janvier 2020
Promoteur – Intermédiaire Financier
ITM ISOTOPEN TECHNOLOGIEN MUENCHEN AGLieu
Description
The project concerns RDI investments of a proprietary portfolio of nuclear medicine solutions for diagnosis and treatment of cancer, addressing a range of indications such as neuroendocrine tumours, bone metastases or prostate cancers. This portfolio includes new radionuclides and radiopharmaceuticals in various stages of clinical development, covering discovery, pre-clinical and clinical (Phase I-III) and technical validation phases.
Objectifs
The project falls within the scope of the Horizon 2020 programme Societal Challenges (Health, Demographic Change and Wellbeing).
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 40 million
Coût total (montant approximatif)
EUR 92 million
Aspects environnementaux
The project mainly concerns investments in R&D (process development, clinical studies, regulatory development/production capacity, etc.) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an EIA under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.
Statut
Signé - 20/12/2019